search
Back to results

Long-term Open-Label Safety Study to Evaluate EN3409

Primary Purpose

Low Back Pain, Osteoarthritis, Neuropathic Pain

Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
EN3409
Sponsored by
BioDelivery Sciences International
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Low Back Pain focused on measuring Chronic Pain, CLBP, Chronic Low Back Pain, Back Pain, Osteoarthritis, OA, Neuropathic Pain, Nerve pain, Painful neuropathy

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Female subjects who are practicing abstinence or using a medically acceptable form of contraception or have been postmenopausal, biologically sterile, or surgically sterile for more than 1 year
  • Male subjects who are practicing abstinence, surgically sterile, or are using a medically acceptable form of contraception
  • De Novo subject with a clinical diagnosis of moderate to severe noncancer-related CP (eg, CLBP, OA, neuropathic pain) for ≥ 3 months
  • De Novo subject that is treating their CP with a stable daily maintenance dose of ATC opioid analgesic medication equivalent to ≥ 60 mg and ≤ 160 mg Morphine Sulfate Equivalent (MSE) per day for ≥ 4 weeks
  • Stable health, as determined by the Principal Investigator
  • Subject is willing and able to comply with all protocol required visits and assessments
  • Rollover subject who has completed the 12-week Double-blind Treatment Phase in the EN3409-307/308 clinical study

Exclusion Criteria:

  • A history or current evidence of any clinically significant disorder or any other condition, which in the opinion of the investigator, would jeopardize the safety of the subject or impact the validity of the study results
  • Females who are pregnant, breastfeeding, or plan to become pregnant during the study
  • Current cancer-related pain or received chemotherapy within 6 months of screening
  • Subjects receiving opioid analgesic medication < 60 mg MSE per day within 28 days of screening
  • De novo subjects receiving opioid analgesic medication at doses of > 160 mg MSE per day within 28 days of screening
  • Subjects with a history of other chronic painful conditions, other than the index CP condition, which require frequent analgesic medication
  • Reflex sympathetic dystrophy or causalgia (complex regional pain syndrome), acute spinal cord compression, cauda equina compression, acute nerve root compression, meningitis, or discitis
  • History of allergy or contraindications to any opioid or acetaminophen
  • Surgical procedure for relief of pain within 6 months, or nerve/plexus block within 28 days of screening
  • Hypokalemia or clinically unstable cardiac disease
  • Moderate to severe hepatic impairment
  • Moderate to severe renal impairment
  • Current or past history of alcohol or substance
  • Positive urine toxicology screen for drugs of abuse
  • History of abnormalities on physical exam, vital signs, ECG, or lab values

Sites / Locations

  • Parkway Medical Center
  • Horizon Research Group, Inc
  • Arizona Research Center
  • Global Research, LLC
  • Synergy Clinical Research Center of Escondido
  • RX Clinical Research, Inc.
  • Long Beach Center for Clinical Research
  • Adam D. Karns, MD
  • Stamford Therapeutics Consortium
  • Clinical Research of West Florida, Inc.
  • Century Clinical Research, Inc.
  • Avail Clinical Research, LLC
  • Florida Health Center
  • Eastern Research, Inc.
  • Southeast Clinical Research, LLC
  • Health Awareness, Inc.
  • Research Centers of America, LLC
  • Compass Research, LLC
  • Ribo Research LLC DBA Peninsula Research
  • Gold Coast Research, LLC
  • Progressive Medical Research
  • Clinical Research of West Florida, Inc.
  • Palm Beach Research Center
  • National Pain Research Institute, LLC
  • River Birch Research Alliance, LLC
  • Drug Studies America
  • Taylor Research, LLC
  • In-Quest Medical Research, LLC
  • Global Scientific Innovations
  • Integrated Clinical Trials Services, Inc.
  • Willis-Knighton Physician Network
  • Clinical Trials Management, LLC
  • Best Clinical Trials, LLC
  • River Cities Clinical Research Center
  • New England Center for Clinical Research, Inc.
  • Great Lakes Research Group, Inc.
  • Cadillac Clinical Research
  • The Center for Clinical Trials
  • Long Island Gastrointestinal Research Group
  • Upstate Clinical Research Associates
  • The Center for Clinical Research
  • Plains Medical Clinic, LLC
  • Clinical Inquest Center, Ltd
  • New Horizons Clinical Research
  • Prestige Clinical Research
  • Optimed Research, Ltd.
  • Brandywine Clinical Research
  • Altoona Center for Clinical Research
  • Pain Specialists of Charleston, P.A.
  • Health Concepts
  • FutureSearch Clinical Trials
  • KRK Medical Research
  • FutureSearch Trials of Dallas, LP
  • Advanced Clinical Research of Houston
  • Innovative Clinical Trials
  • Highland Clinical Research
  • Clinical Investigations Specialist, Inc.

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

EN3409

Arm Description

Buprenorphine HCI Buccal File at doses ranging from 300-900 mcg twice daily

Outcomes

Primary Outcome Measures

Change From Baseline to Week 48 in Daily Average NRS Pain Intensity Score
The NRS Pain intensity score is a segmented version of a visual analog scale used to measure pain. The scale is from 0 (no pain) to 10. Scores between greater than 0 and 3 are considered mild pain, scores from greater than 3 to 6 are moderate and greater than 6 to 10 are severe. The daily average is calculated and the change from baseline at week 48 is presented.

Secondary Outcome Measures

Full Information

First Posted
December 19, 2012
Last Updated
September 20, 2018
Sponsor
BioDelivery Sciences International
search

1. Study Identification

Unique Protocol Identification Number
NCT01755546
Brief Title
Long-term Open-Label Safety Study to Evaluate EN3409
Official Title
A Phase 3, Open-label, Long-term Study to Evaluate the Safety, Tolerability, and Analgesic Efficacy of BEMA® Buprenorphine in Subjects With Moderate to Severe Chronic Pain Requiring Continuous Around-the-Clock Opioid Analgesia for an Extended Period of Time
Study Type
Interventional

2. Study Status

Record Verification Date
March 2018
Overall Recruitment Status
Completed
Study Start Date
December 2012 (undefined)
Primary Completion Date
October 2014 (Actual)
Study Completion Date
November 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
BioDelivery Sciences International

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of the long-terms study is to evaluate the safety, tolerability, and analgesic efficacy of EN3409 in subjects with moderate to severe chronic pain requiring continuous around-the-clock opioid analgesia for an extended period of time.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Low Back Pain, Osteoarthritis, Neuropathic Pain
Keywords
Chronic Pain, CLBP, Chronic Low Back Pain, Back Pain, Osteoarthritis, OA, Neuropathic Pain, Nerve pain, Painful neuropathy

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
304 (Actual)

8. Arms, Groups, and Interventions

Arm Title
EN3409
Arm Type
Experimental
Arm Description
Buprenorphine HCI Buccal File at doses ranging from 300-900 mcg twice daily
Intervention Type
Drug
Intervention Name(s)
EN3409
Other Intervention Name(s)
Buprenorphine HCI Buccal Film 300-900 mcg twice daily
Intervention Description
Open-Label Buprenorphine HCI Buccal Film at doses 300-900 mcg twice daily
Primary Outcome Measure Information:
Title
Change From Baseline to Week 48 in Daily Average NRS Pain Intensity Score
Description
The NRS Pain intensity score is a segmented version of a visual analog scale used to measure pain. The scale is from 0 (no pain) to 10. Scores between greater than 0 and 3 are considered mild pain, scores from greater than 3 to 6 are moderate and greater than 6 to 10 are severe. The daily average is calculated and the change from baseline at week 48 is presented.
Time Frame
48 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Female subjects who are practicing abstinence or using a medically acceptable form of contraception or have been postmenopausal, biologically sterile, or surgically sterile for more than 1 year Male subjects who are practicing abstinence, surgically sterile, or are using a medically acceptable form of contraception De Novo subject with a clinical diagnosis of moderate to severe noncancer-related CP (eg, CLBP, OA, neuropathic pain) for ≥ 3 months De Novo subject that is treating their CP with a stable daily maintenance dose of ATC opioid analgesic medication equivalent to ≥ 60 mg and ≤ 160 mg Morphine Sulfate Equivalent (MSE) per day for ≥ 4 weeks Stable health, as determined by the Principal Investigator Subject is willing and able to comply with all protocol required visits and assessments Rollover subject who has completed the 12-week Double-blind Treatment Phase in the EN3409-307/308 clinical study Exclusion Criteria: A history or current evidence of any clinically significant disorder or any other condition, which in the opinion of the investigator, would jeopardize the safety of the subject or impact the validity of the study results Females who are pregnant, breastfeeding, or plan to become pregnant during the study Current cancer-related pain or received chemotherapy within 6 months of screening Subjects receiving opioid analgesic medication < 60 mg MSE per day within 28 days of screening De novo subjects receiving opioid analgesic medication at doses of > 160 mg MSE per day within 28 days of screening Subjects with a history of other chronic painful conditions, other than the index CP condition, which require frequent analgesic medication Reflex sympathetic dystrophy or causalgia (complex regional pain syndrome), acute spinal cord compression, cauda equina compression, acute nerve root compression, meningitis, or discitis History of allergy or contraindications to any opioid or acetaminophen Surgical procedure for relief of pain within 6 months, or nerve/plexus block within 28 days of screening Hypokalemia or clinically unstable cardiac disease Moderate to severe hepatic impairment Moderate to severe renal impairment Current or past history of alcohol or substance Positive urine toxicology screen for drugs of abuse History of abnormalities on physical exam, vital signs, ECG, or lab values
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Andrew Finn, PharmD
Organizational Affiliation
BioDelivary Sciences Internantional, Inc.
Official's Role
Study Director
Facility Information:
Facility Name
Parkway Medical Center
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35215
Country
United States
Facility Name
Horizon Research Group, Inc
City
Mobile
State/Province
Alabama
ZIP/Postal Code
36608
Country
United States
Facility Name
Arizona Research Center
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85023
Country
United States
Facility Name
Global Research, LLC
City
Anaheim
State/Province
California
ZIP/Postal Code
92804
Country
United States
Facility Name
Synergy Clinical Research Center of Escondido
City
Escondido
State/Province
California
ZIP/Postal Code
92025
Country
United States
Facility Name
RX Clinical Research, Inc.
City
Garden Grove
State/Province
California
ZIP/Postal Code
92843
Country
United States
Facility Name
Long Beach Center for Clinical Research
City
Long Beach
State/Province
California
ZIP/Postal Code
90807
Country
United States
Facility Name
Adam D. Karns, MD
City
Los Angeles
State/Province
California
ZIP/Postal Code
90036
Country
United States
Facility Name
Stamford Therapeutics Consortium
City
Stamford
State/Province
Connecticut
ZIP/Postal Code
06905
Country
United States
Facility Name
Clinical Research of West Florida, Inc.
City
Clearwater
State/Province
Florida
ZIP/Postal Code
33765
Country
United States
Facility Name
Century Clinical Research, Inc.
City
Daytona Beach
State/Province
Florida
ZIP/Postal Code
32117
Country
United States
Facility Name
Avail Clinical Research, LLC
City
DeLand
State/Province
Florida
ZIP/Postal Code
32720
Country
United States
Facility Name
Florida Health Center
City
Fort Lauderdale
State/Province
Florida
ZIP/Postal Code
33312
Country
United States
Facility Name
Eastern Research, Inc.
City
Hialeah
State/Province
Florida
ZIP/Postal Code
33013
Country
United States
Facility Name
Southeast Clinical Research, LLC
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32216
Country
United States
Facility Name
Health Awareness, Inc.
City
Jupiter
State/Province
Florida
ZIP/Postal Code
33458
Country
United States
Facility Name
Research Centers of America, LLC
City
Oakland Park
State/Province
Florida
ZIP/Postal Code
33334
Country
United States
Facility Name
Compass Research, LLC
City
Orlando
State/Province
Florida
ZIP/Postal Code
32806
Country
United States
Facility Name
Ribo Research LLC DBA Peninsula Research
City
Ormond Beach
State/Province
Florida
ZIP/Postal Code
32806
Country
United States
Facility Name
Gold Coast Research, LLC
City
Plantation
State/Province
Florida
ZIP/Postal Code
33317
Country
United States
Facility Name
Progressive Medical Research
City
Port Orange
State/Province
Florida
ZIP/Postal Code
32127
Country
United States
Facility Name
Clinical Research of West Florida, Inc.
City
Tampa
State/Province
Florida
ZIP/Postal Code
33603
Country
United States
Facility Name
Palm Beach Research Center
City
West Palm Beach
State/Province
Florida
ZIP/Postal Code
33409
Country
United States
Facility Name
National Pain Research Institute, LLC
City
Winter Park
State/Province
Florida
ZIP/Postal Code
32789
Country
United States
Facility Name
River Birch Research Alliance, LLC
City
Blue Ridge
State/Province
Georgia
ZIP/Postal Code
30513
Country
United States
Facility Name
Drug Studies America
City
Marietta
State/Province
Georgia
ZIP/Postal Code
30060
Country
United States
Facility Name
Taylor Research, LLC
City
Marietta
State/Province
Georgia
ZIP/Postal Code
30060
Country
United States
Facility Name
In-Quest Medical Research, LLC
City
Norcross
State/Province
Georgia
ZIP/Postal Code
30092
Country
United States
Facility Name
Global Scientific Innovations
City
Evansville
State/Province
Indiana
ZIP/Postal Code
47714
Country
United States
Facility Name
Integrated Clinical Trials Services, Inc.
City
West Des Moines
State/Province
Iowa
ZIP/Postal Code
50265
Country
United States
Facility Name
Willis-Knighton Physician Network
City
Bossier City
State/Province
Louisiana
ZIP/Postal Code
71111
Country
United States
Facility Name
Clinical Trials Management, LLC
City
Metairie
State/Province
Louisiana
ZIP/Postal Code
70006
Country
United States
Facility Name
Best Clinical Trials, LLC
City
New Orleans
State/Province
Louisiana
ZIP/Postal Code
70115
Country
United States
Facility Name
River Cities Clinical Research Center
City
Shreveport
State/Province
Louisiana
ZIP/Postal Code
71105
Country
United States
Facility Name
New England Center for Clinical Research, Inc.
City
Fall River
State/Province
Massachusetts
ZIP/Postal Code
02720
Country
United States
Facility Name
Great Lakes Research Group, Inc.
City
Bay City
State/Province
Michigan
ZIP/Postal Code
48706
Country
United States
Facility Name
Cadillac Clinical Research
City
Cadillac
State/Province
Michigan
ZIP/Postal Code
49601
Country
United States
Facility Name
The Center for Clinical Trials
City
Biloxi
State/Province
Mississippi
ZIP/Postal Code
39531
Country
United States
Facility Name
Long Island Gastrointestinal Research Group
City
Great Neck
State/Province
New York
ZIP/Postal Code
11023
Country
United States
Facility Name
Upstate Clinical Research Associates
City
Williamsville
State/Province
New York
ZIP/Postal Code
14221
Country
United States
Facility Name
The Center for Clinical Research
City
Winston-Salem
State/Province
North Carolina
ZIP/Postal Code
27103
Country
United States
Facility Name
Plains Medical Clinic, LLC
City
Fargo
State/Province
North Dakota
ZIP/Postal Code
58104
Country
United States
Facility Name
Clinical Inquest Center, Ltd
City
Beavercreek
State/Province
Ohio
ZIP/Postal Code
45432
Country
United States
Facility Name
New Horizons Clinical Research
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45242
Country
United States
Facility Name
Prestige Clinical Research
City
Franklin
State/Province
Ohio
ZIP/Postal Code
45005
Country
United States
Facility Name
Optimed Research, Ltd.
City
Tiffin
State/Province
Ohio
ZIP/Postal Code
44883
Country
United States
Facility Name
Brandywine Clinical Research
City
Downingtown
State/Province
Pennsylvania
ZIP/Postal Code
19335
Country
United States
Facility Name
Altoona Center for Clinical Research
City
Duncansville
State/Province
Pennsylvania
ZIP/Postal Code
16635
Country
United States
Facility Name
Pain Specialists of Charleston, P.A.
City
Charleston
State/Province
South Carolina
ZIP/Postal Code
29406
Country
United States
Facility Name
Health Concepts
City
Rapid City
State/Province
South Dakota
ZIP/Postal Code
57702
Country
United States
Facility Name
FutureSearch Clinical Trials
City
Austin
State/Province
Texas
ZIP/Postal Code
78731
Country
United States
Facility Name
KRK Medical Research
City
Dallas
State/Province
Texas
ZIP/Postal Code
75230
Country
United States
Facility Name
FutureSearch Trials of Dallas, LP
City
Dallas
State/Province
Texas
ZIP/Postal Code
75231
Country
United States
Facility Name
Advanced Clinical Research of Houston
City
Houston
State/Province
Texas
ZIP/Postal Code
77062
Country
United States
Facility Name
Innovative Clinical Trials
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States
Facility Name
Highland Clinical Research
City
Salt Lake City
State/Province
Utah
ZIP/Postal Code
84124
Country
United States
Facility Name
Clinical Investigations Specialist, Inc.
City
Kenosha
State/Province
Wisconsin
ZIP/Postal Code
53142
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Long-term Open-Label Safety Study to Evaluate EN3409

We'll reach out to this number within 24 hrs